Acute doxorubicin-induced cardiotoxicity is associated with matrix metalloproteinase-2 alterations in rats

Cellular Physiology and Biochemistry

Volumn 35, Issue 5, 2015, Pages 1924-1933

  Polegato, Bertha Furlan ^a   Minicucci, Marcos Ferreira ^a   Azevedo, Paula Schmidt ^a   Carvalho, Robson Francisco ^a   Chiuso Minicucci, Fernanda ^a   Pereira, Elenize Jamas ^a   Paiva, Sergio Alberto Rupp ^a   Zornoff, Leonardo Antônio Mamede ^a   Okoshi, Marina Politi ^a   Matsubara, Beatriz Bojikian ^a   Matsubara, Luiz Shiguero ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Acute cardiotoxicity; Cytokines; Doxorubicin; Isolated heart study; Matrix metalloproteinase; Phospholamban; Ryanodine receptor; Serca 2a

Indexed keywords

CALCIUM; DOXORUBICIN; GAMMA INTERFERON; GELATINASE A; INTERCELLULAR ADHESION MOLECULE 1; PHOSPHOLAMBAN; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; INTERLEUKIN 10; KETAMINE; XYLAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CARDIOTOXICITY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART FUNCTION; IN VITRO STUDY; IN VIVO STUDY; ISOLATED HEART; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; WISTAR RAT; ZYMOGRAPHY; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; HEART; HEART MUSCLE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

RATTUS; RATTUS NORVEGICUS;

ANIMALS; BLOOD PRESSURE; CARDIOTOXICITY; DOXORUBICIN; ECHOCARDIOGRAPHY; HEART; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; INTERLEUKIN-10; KETAMINE; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIUM; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA; XYLAZINE;

EID: 84927944909     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000374001     Document Type: Article

References (52)

1. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A: Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337.
2. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.
3. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K: Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention-review of the literature. Med Sci Monit 2000;6:411-420.
4. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM: Risk Factors for Doxorubicin-lnduced Congestive Heart Failure. Ann Intern Med 1979;91:710-717.
5. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC: Early anthracycline cardiotoxicity. Am J Med. 1978;65:823-832.
6. Shi Y, Moon M, Dawood S, McManus B, Liu PP: Mechanisms and management of doxorubicin cardiotoxicity. Herz 2011;36:296-304.
7. Pereira GC, Pereira SP, Pereira CV, Lumini JA, Magalhaes J, Ascensao A, Santos MS, Moreno AJ, Oliveira PJ: Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific. PLoS One 2012;7:e38867.
8. Robert J: Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovasc Toxicol 2007;7:135-139.
9. Yi X, Bekeredjian R, DeFilippis NJ, Siddiquee Z, Fernandez E, Shohet RV: Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 2006;290:H1098-H1102.
10. Kizaki K, Ito R, Okada M, Yoshioka K, Uchide T, Temma K, Mutoh K, Uechi M, Hara Y: Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. Pharmacol Res 2006;53:341-346.
11. Spinale FG: Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function. Physiol Rev 2007;87:1285-1342.
12. Ivanova M, Dovinova I, Okruhlicova L, Tribulova N, Simoncikova P, Barte-ková M, Vlkoviová J, Baraník M: Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats. Acta Pharmacol Sin 2012;33:459-469.
13. Bai P, Mabley JG, Liaudet L, Virag L, Szabo C, Pacher P: Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep 2004;11:505-508.
14. Martinez PF, Okoshi K, Zornoff LA, Oliveira SA, Jr., Campos DH, Lima AR, Damatto RL, Cezar MD, Bonomo C, Guizoni DM, Padovani CR, Cicogna AC, Okoshi MP: Echocardiographic detection of congestive heart failure in postinfarction rats. J Appl Physiol 2011;111:543-551.
15. de Paiva SA, Zornoff LA, Okoshi MP, Okoshi K, Matsubara LS, Matsubara BB, Cicogna AC, Campana AO: Ventricular remodeling induced by retinoic acid supplementation in adult rats. Am J Physiol Heart Circ Physiol 2003;284:H2242-H2246.
16. Rosa CM, Xavier NP, Henrique Campos D, Fernandes AA, Cezar MD, Martinez PF, Cicogna AC, Gimenes C, Gimenes R, Okoshi MP, Okoshi K: Diabetes mellitus activates fetal gene program and intensifies cardiac remodeling and oxidative stress in aged spontaneously hypertensive rats. Cardiovasc Diabetol 2013;12:152.
17. Cezar MDM, Damatto RL, Martinez PF, Lima ARR, Campos DHS, Rosa CM, Guizoni DM, Bonomo C, Cicogna AC, Gimenes R, Pagan LU, Okoshi MP, Okoshi K: Aldosterone blockade reduces mortality without changing cardiac remodeling in spontaneously hypertensive rats. Cell Physiol Biochem 2013;32:1275-1287.
18. Zornoff LA, de Paiva SA, Tornero MT, Carvalho MS, Tucci PJ: Influence of mannitol added to the nutrient solution on the mechanical performance and on the degree of myocardial edema of isolated hearts of rats. Arq Bras Cardiol 1995;64:225-229.
19. Paiva SA, Novo R, Matsubara BB, Matsubara LS, Azevedo PS, Minicucci MF, Campana AO, Zornoff LA: Betacarotene attenuates the paradoxical effect of tobacco smoke on the mortality of rats after experimental myocardial infarction. J Nutr 2005;135:2109-2113.
20. Matsubara BB, Matsubara LS, Zornoff LA, Franco M, Janicki JS. Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats. Basic Res Cardiol 1998;93:173-181.
21. Okoshi K, Matsubara LS, Okoshi MP, Cicogna AC, Fioretto JR, Padovani CR, et al: Food restriction-induced myocardial dysfunction demonstrated by the combination of in vivo and in vitro studies. Nutr Res 2002;22:1353-1364.
22. Okoshi K, Fioretto JR, Okoshi MP, Cicogna AC, Aragon FF, Matsubara LS, Matsubara BB: Food restriction induces in vivo ventricular dysfunction in spontaneously hypertensive rats without impairment of in vitro myocardial contractility. Braz J Med Biol Res 2004;37:607-613.
23. Lima ARR, Martinez PF, Damatto RL, Cezar MDM, Guizoni DM, Bonomo C, Oliveira Jr. SA, Dal Pai-Silva M, Zornoff LAM, Okoshi K, Okoshi MP: Heart failure-induced diaphragm myopathy. Cell Physiol Biochem 2014;34:333-345.
24. Tyagi SC, Matsubara L, Weber KT: Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem 1993;26:191-198.
25. dos Santos PP, Nogueira BF, Rafacho BP, Azevedo PS, Polegato BF, Chiuso-Minicucci F, Bonomo C, Roscani MG, Zorzella-Pezavento SF, Tanni SE, Pereira EJ, Okoshi MP, Paiva SA, Zornoff LA, Minicucci MF: Aldosterone is not involved in the ventricular remodeling process induced by tobacco smoke exposure. Cell Physiol Biochem 2012;30:1191-1201.
26. Owen SV, Froman RD: Uses and abuses of the analysis of covariance. Res Nurs Health 1998;2:557-562.
27. Yeung TK, Simmonds RH, Hopewell JW: A Functional Assessment of the Relative Cardiotoxicity of Adriamycin and Epirubicin in the Rat. Radiotherapy and Oncology 1989;15:275-284.
28. Hayward R, Hydock DS: Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci 2007;46:20-32.
29. Liu FF, Stone JR, Schuldt AJ, Okoshi K, Okoshi MP, Nakayama M, Ho KK, Manning WJ, Marchionni MA, Lorell BH, Morgan JP, Yan X: Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicininduced heart failure. Am J Physiol Heart Circ Physiol 2005;289:H660-H666.
30. Weinberg LE, Singal PK: Refractory heart failure and age-related differences in adriamycin-induced myocardial changes in rats. Can J Physiol Pharmacol 1987;65:1957-1965.
31. Toko H, Oka T, Zou Y, Sakamoto M, Mizukami M, Sano M, Yamamoto R, Sugaya T, Komuro I: Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 2002;25:597-603.
32. Weinstein DM, Mihm MJ, Bauer JA: Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther 2000;294:396-401.
33. Deschamps AM, Spinale FG: Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 2006;69:666-676.
34. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001;103:2303-2309.
35. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L: Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 1998;82:482-495.
36. Yarbrough WM, Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Escobar GP, Joffs C, Lucas DG, Crawford FA Jr, Spinale FG: Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg 2003;125:602-610.
37. Kandasamy AD, Chow AK, Ali MA, Schulz R: Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 2010;85:413-423.
38. Schulz R: Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007;47:211-242.
39. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL: Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012;52:1213-1225.
40. Chaiswing L, Cole MP, Ittarat W, Szweda LI, St Clair DK, Oberley TD: Manganese superoxide dismutase and inducible nitric oxide synthase modify early oxidative events in acute adriamycin-induced mitochondrial toxicity. Mol Cancer Ther 2005;4:1056-1064.
41. Dodd DA, Atkinson JB, Olson RD, Buck S, Cusack BJ, Fleischer S, Boucek RJ Jr: Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest 1993;91:1697-1705.
42. Boucek Jr. RJ, Dodd DA, Atkinson JB, Oquist N, Olson RD: Contractile failure in chronic doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol 1997;29:2631-2640.
43. Arai M, Tomaru K, Takizawa T, Sekiguchi K, Yokoyama T, Suzuki T, Nagai R: Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol 1998;30:243-254.
44. Kim SY, Kim SJ, Kim BJ, Rah SY, Chung SM, Im MJ, Kim UH: Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Experimental and Molecular Medicine 2006;38:535-545.
45. Mushlin PS, Cusack BJ, Boucek RJ, Jr., Andrejuk T, Li X, Olson RD: Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 1993;110:975-982.
46. Ikeda Y, Hoshijima M, Chien KR: Toward biologically targeted therapy of calcium cycling defects in heart failure. Physiology 2008;23:6-16.
47. Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK: Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol 2003;3:16.
48. Zhu JZ, Zhang J, Xiang D, Zhang ZH, Zhang L, Wu MY, Zhu S, Zhang R, Han W: Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. European Journal of Pharmacology 2010;643:247-253.
49. Singal PK, Lou H, Danelisen I: Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. Journal of Molecular and Cellular Cardiology 2004;36:683-690.
50. Teng LL, Shao L, Zhao YT, Yu X, Zhang DF, Zhang H: The beneficial effect of n-3 polyunsaturated fatty acids on doxorubicin-induced chronic heart failure in rats. J Int Med Res 2010;38:940-948.
51. Mong MC, Hsia TC, Yin MC: Dietary trans fats enhance doxorubicin-induced cardiotoxicity in mice. J Food Sci 2013;78:H1621-H1628.
52. Lin MC, Yin MC: Preventive effects of ellagic acid against doxorubicin-induced cardio-toxicity in mice. Cardiovasc Toxicol 2013;13:185-193.